The Ottawa AF Cardioversion Protocol

Atrial Fibrillation Clinical Trial

Official title:

Developing a Standardized Atrial Fibrillation Cardioversion Protocol

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02192957
• Other study ID #: 20140415
• Secondary ID: Form ID 2788
• Status: Completed
• Phase: N/A
• Start date: August 2015
• Est. completion date: April 2018

Study information

• Verified date: September 2019
• Source: Ottawa Heart Institute Research Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Atrial fibrillation is an abnormal heart rhythm in which the top chambers of the heart (the atrial chambers) beat very fast. Electrical cardioversion is a technique to convert heart rhythm from AF to normal rhythm. The technique sends out a brief electric shock to the heart through electrodes (paddles or skin patches) applied to the outside of the chest wall. The shock resets the heart rhythm back to its normal pattern.

This technique is practiced at many hospitals, including the Heart Institute, and is not experimental. However no detailed national or international guidelines exist to assist physicians in performing cardioversion. Physicians use a variety of methods. Electrical cardioversion does not always restore normal rhythm. Adjusting the electrical energy dose, changing the electrode position and applying pressure to the electrodes may improve the success rate.

This study will look at the safety and efficacy of a protocol (step by step method) for electrical cardioversion. The protocol prescribes the electrical energy dose, the electrode position and the application of pressure to the electrodes the physician will use. The individual elements of the protocol (energy dose, electrode position and pressure application) are often used by physician in clinical practice but not necessarily in the step by step order.

The purpose of this study is to get all doctors to follow a standard protocol 'the Ottawa AF cardioversion protocol'. We think that using this protocol will improve overall cardioversion success rates. The results of this study may change usual practice in Canada and in other countries.

All supplies, equipment and medications used in the protocol cardioversion are approved by Health Canada.

We estimate that 389 participants from the University of Ottawa Heart Institute will be enrolled in the study over the next 2 years. The results will be compared with a group of previous patients.

Description:

Study design:

All eligible and consenting patients will undergo elective electrical cardioversion for atrial fibrillation (AF) using the Ottawa AF protocol.The fact that the physician follows the protocol makes this experimental. Aside from following the protocol, subjects will receive standard care before, during and after the procedure. Outcomes of the procedure and clinical features know to affect cardioversion efficacy will be collected. These will be compared to a group of 500 previous patients who underwent elective electrical cardioversion for AF at the Heart Institute.

Methodology:

The Ottawa AF protocol prescribes the electrical energy dose, the electrode position and the application of pressure to the electrodes the physician will use. The individual elements of the protocol (energy dose, electrode position and pressure application) are often used by physician in clinical practice but not necessarily in the step by step order.

The Ottawa AF protocol prescribes the following:

• the starting energy dose (200 J) and electrode placement (anterior-posterior)

• the second electrode placement (anterior-lateral) if the first shock is not successful

• addition of pressure to electrodes if second shock is not successful

• step up of energy dose (360 J) along with pressure to electrodes if third shock is not successful

• optional further steps at physician's choice if fourth shock is not successful

Recruitment information / eligibility

• Status: Completed
• Enrollment: 389
• Est. completion date: April 2018
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Documented atrial fibrillation within last 12 months

• On continuous systemic oral anticoagulation for 28 days prior to the day of cardioversion or must have undergone a recent (< 48 hrs) trans-esophageal echocardiogram prior to the day of cardioversion

• Able to provide informed consent

Exclusion Criteria:

• Presence of intracardiac thrombus

• Pregnancy

Related Conditions & MeSH terms

• Atrial Fibrillation

Intervention

Device:
• Lifepak 20E Defibrillator, Licence No: 61944
Intervention will be carried out using Health Canada approved devices for electrical cardioversion, following the steps pre-specified in the Ottawa AF Protocol. Ottawa AF Cardioversion

Locations

Country	Name	City	State
Canada	University of Ottawa Heart Institution	Ottawa	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
David Birnie

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Ramirez FD, Sadek MM, Boileau I, Cleland M, Nery PB, Nair GM, Redpath CJ, Green MS, Davis DR, Charron K, Henne J, Zakutney T, Beanlands RSB, Hibbert B, Wells GA, Birnie DH. Evaluation of a novel cardioversion intervention for atrial fibrillation: the Otta — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Adverse Events	adverse events related to cardioversion	participants will be followed for the duration of hospital stay for elective cardioversion, an expected average of 2 hours.
Primary	Last shock efficacy	Last shock efficacy defined as success ( two or more beats of sinus rhythm) or failure.	immediately after cardioversion